Ludovica Borsoi

Government, Health and Not for Profit

Biography

Latest publications

ARMENI P., BERTOLANI A., BORSOI L., COSTA F. La spesa sanitaria: composizione ed evoluzione in Rapporto OASI 2021 Cergas (Eds),Egea, chap. 3, pp.117-173, 2021
ARMENI P., MEREGAGLIA M., BORSOI L., TORBICA A., CALLEA G. PMD16 What Factors Do Clinicians Value Most in Selecting Physician Preference Items? a Survey in Orthopedics Using Discrete Choice Experiment and Best-Worst Scaling Value In Health, 2021, vol.24, pp.S126
TARRICONE R., AMATUCCI F., ARMENI P., BANKS H., BORSOI L., CALLEA G., CIANI O., COSTA F., FEDERICI C. B., TORBICA A., Marletta M. Establishing a national HTA program for medical devices in Italy: Overhauling a fragmented system to ensure value and equal access to new medical technologies Health Policy, 2021, vol.125, no. 5, pp.602-608
ROGNONI C., Cuccurullo D., BORSOI L., Bonavina L., Asti E., Crovella F., Bassi U., Carbone G., Guerini F., De Paolis P., Pessione S., Greco V. M., Baccarini E., Soliani G., Sagnelli C., Crovella C., Trapani V., De Nisco C., Eugeni E., Zanzi F., De Nicola E., Marioni A., Rosignoli A., Silvestro R., TARRICONE R., Piccoli M. Clinical outcomes and quality of life associated with the use of a biosynthetic mesh for complex ventral hernia repair: analysis of the “Italian Hernia Club” registry Scientific Reports, 2020, vol.10, no. 1
ARMENI P., BORSOI L., FORNARO G., JOMMI C., COLOMBO N., COSTA F. Cost-Effectiveness and Net Monetary Benefit of olaparib Maintenance Therapy Versus No Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-Mutated Ovarian Cancer in the Italian National Health Service Clinical Therapeutics, 2020, vol.42, no. 7, pp.1192-1209
ARMENI P., BORSOI L., FORNARO G., JOMMI C., Grossi F., COSTA F. Cost-effectiveness and Net Monetary Benefit of Durvalumab Consolidation Therapy Versus No Consolidation Therapy After Chemoradiotherapy in Stage III Non–small Cell Lung Cancer in the Italian National Health Service Clinical Therapeutics, 2020, vol.42, no. 5, pp.830-847

Director

VALUE-BASED MEDTECH: HOW TO SUCCEED IN A CHALLENGING ENVIRONMENT
  • Start date
  • Duration
  • Format
  • Language
  • 3 oct 2022
  • 3,5 days
  • Blended
  • English

Learning the key elements for success in the medical-device sector: new European Regulations, clinical and economic evidence to be generated, new methods of purchasing, etc.